BR112018010766A8 - proteínas de ligação ao cd131 e usos das mesmas - Google Patents

proteínas de ligação ao cd131 e usos das mesmas

Info

Publication number
BR112018010766A8
BR112018010766A8 BR112018010766A BR112018010766A BR112018010766A8 BR 112018010766 A8 BR112018010766 A8 BR 112018010766A8 BR 112018010766 A BR112018010766 A BR 112018010766A BR 112018010766 A BR112018010766 A BR 112018010766A BR 112018010766 A8 BR112018010766 A8 BR 112018010766A8
Authority
BR
Brazil
Prior art keywords
binding proteins
antigen
binding domain
binds
binding
Prior art date
Application number
BR112018010766A
Other languages
English (en)
Other versions
BR112018010766A2 (pt
Inventor
Owczarek Catherine
Edwards Kirsten
Panousis Kosta
Hardy Matthew
Wilson Nicholas
Rayzman Veronika
Original Assignee
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015904924A external-priority patent/AU2015904924A0/en
Application filed by Csl Ltd filed Critical Csl Ltd
Publication of BR112018010766A2 publication Critical patent/BR112018010766A2/pt
Publication of BR112018010766A8 publication Critical patent/BR112018010766A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Abstract

a presente divulgação fornece uma proteína de ligação à cd131 que compreende um domínio de ligação ao antígeno de um anticorpo, em que o domínio de ligação ao antígeno se liga a ou se liga especificamente ao cd131 e neutraliza a sinalização por interleucina il-3 (il) 3, il-5 e fator estimulante de colônia de granulócitos e macrófagos (gm- csf), e usos dos mesmos.
BR112018010766A 2015-11-27 2016-11-25 proteínas de ligação ao cd131 e usos das mesmas BR112018010766A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015904924 2015-11-27
AU2015904924A AU2015904924A0 (en) 2015-11-27 Cd131 binding proteins and uses thereof
PCT/AU2016/051158 WO2017088028A1 (en) 2015-11-27 2016-11-25 Cd131 binding proteins and uses thereof

Publications (2)

Publication Number Publication Date
BR112018010766A2 BR112018010766A2 (pt) 2018-11-21
BR112018010766A8 true BR112018010766A8 (pt) 2019-02-26

Family

ID=58762858

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010766A BR112018010766A8 (pt) 2015-11-27 2016-11-25 proteínas de ligação ao cd131 e usos das mesmas

Country Status (13)

Country Link
US (2) US10894834B2 (pt)
EP (1) EP3380514A4 (pt)
JP (1) JP6882287B2 (pt)
KR (1) KR20180084134A (pt)
CN (2) CN108368167B (pt)
AU (1) AU2016361462B2 (pt)
BR (1) BR112018010766A8 (pt)
CA (1) CA3003200A1 (pt)
HK (1) HK1253533A1 (pt)
IL (1) IL259519B (pt)
MX (1) MX2018006410A (pt)
SG (2) SG10201912051TA (pt)
WO (1) WO2017088028A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6882287B2 (ja) * 2015-11-27 2021-06-02 シーエスエル リミティド Ｃｄ１３１結合タンパク質とその利用
CN108586606A (zh) * 2018-04-24 2018-09-28 上海药明生物技术有限公司 一种用于去除抗体蛋白中内毒素的方法
US20230406943A1 (en) * 2020-12-04 2023-12-21 CSL Innovation Pty Ltd Methods for treating inflammatory skin conditions
WO2022133519A1 (en) * 2020-12-21 2022-06-30 CSL Innovation Pty Ltd Methods for treating or preventing acute respiratory distress syndrome
CN117836326A (zh) * 2021-08-26 2024-04-05 协和麒麟株式会社 与cd116和cd131结合的双特异性抗体
WO2023173173A1 (en) * 2022-03-16 2023-09-21 CSL Innovation Pty Ltd Method of treating an eosinophil-associated disease
WO2023192944A1 (en) * 2022-04-01 2023-10-05 The Jackson Laboratory Combination immune checkpoint inhibitor therapies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP525198A0 (en) * 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
CA2362264C (en) * 1999-02-08 2012-05-08 Medvet Science Pty. Ltd. Cytokine-binding domain
AU2002351208A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
EP1467757B1 (en) 2001-12-28 2008-05-07 Amgen Fremont Inc. Use of antibodies against the muc18 antigen
BRPI0510885A (pt) 2004-06-04 2007-12-26 Genentech Inc método de tratamento de lúpus e artigo industrializado
US7329737B2 (en) 2004-08-03 2008-02-12 Dyax Corp. Antibodies that bind hK-1
US7790862B2 (en) * 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
JP6882287B2 (ja) * 2015-11-27 2021-06-02 シーエスエル リミティド Ｃｄ１３１結合タンパク質とその利用

Also Published As

Publication number Publication date
US20190062438A1 (en) 2019-02-28
AU2016361462B2 (en) 2023-09-21
IL259519A (en) 2018-07-31
US11840573B2 (en) 2023-12-12
US10894834B2 (en) 2021-01-19
EP3380514A4 (en) 2019-05-22
JP2019500859A (ja) 2019-01-17
CA3003200A1 (en) 2017-06-01
HK1253533A1 (zh) 2019-06-21
CN116987190A (zh) 2023-11-03
EP3380514A1 (en) 2018-10-03
SG10201912051TA (en) 2020-02-27
BR112018010766A2 (pt) 2018-11-21
CN108368167A (zh) 2018-08-03
SG11201803565UA (en) 2018-06-28
CN108368167B (zh) 2023-09-05
MX2018006410A (es) 2019-01-31
US20210324091A1 (en) 2021-10-21
KR20180084134A (ko) 2018-07-24
WO2017088028A1 (en) 2017-06-01
IL259519B (en) 2022-06-01
RU2018123349A3 (pt) 2020-05-26
JP6882287B2 (ja) 2021-06-02
AU2016361462A1 (en) 2018-05-10
RU2018123349A (ru) 2019-12-27

Similar Documents

Publication Publication Date Title
BR112018010766A2 (pt) proteínas de ligação ao cd131 e usos das mesmas
BR112018014150A2 (pt) anticorpos monoclonais humanizados imunoestimulantes contra interleucina-2 humana, e proteínas de fusão dos mesmos
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
BR112016030670A2 (pt) "imunocitoquina"
BR112018076260A2 (pt) anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
AR105767A1 (es) Proteínas de fusión de unión a gitr multivalentes y multiespecíficas
BR112018010084A2 (pt) ligantes de pd1 e/ou lag3
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
BR112016014022A2 (pt) anticorpos anti-cd3, ácido nucleico isolado, vetor, célula hospedeira, método de produção do anticorpo anti-cd3, imunoconjugado, composição, uso do anticorpo anti-cd3, métodos de tratamento, métodos de intensificação da função imune e kit
CR20180031A (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso
BR112018000475A2 (pt) construtos de anticorpo biespecíficos que se ligam a dll3 e a cd3
BR112017017025A2 (pt) métodos e composições para analizar componentes celulares
EA201591376A1 (ru) Конструкции антител к cdh19 и cd3
MA53742A (fr) Molécules de liaison à l'antigène capables de se lier à cd3 et cd137 mais pas simultanément
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
BR112016001977A2 (pt) septo acústico de vários segmentos
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas
BR112013027829A2 (pt) anticorpos anti-cd40 e método de uso
UY33983A (es) Proteínas de Unión de Tipo Anticuerpo con Región Variable Dual que Tienen Orientación de la Región de Unión con Entrecruzamiento.
BR112018068678A2 (pt) anticorpos anti-mica
BR112019004990A2 (pt) anticorpo que se liga especificamente a il-17a e fragmento funcional do mesmo
BR112017013956B8 (pt) Proteínas de fusão de citocinas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]